Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy Study of Etanercept (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02701205
Recruitment Status : Unknown
Verified March 2016 by Shanghai Celgen Bio-Pharmaceutical Co.,Ltd.
Recruitment status was:  Recruiting
First Posted : March 8, 2016
Last Update Posted : March 8, 2016
Sponsor:
Information provided by (Responsible Party):
Shanghai Celgen Bio-Pharmaceutical Co.,Ltd

Brief Summary:
This is a randomized, double-blind, multicentral clinical trial to investigate the efficacy and safety of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection (Qiangke®) in the treatment of Moderate to Severe Plaque Psoriasis. The primary purpose is to assess the different maintaining treatment programme in Moderate to Severe plaque psoriasis by Qiangke®. And the second purpose is to assess the efficacy and safety of Qiangke® in Moderate to Severe Plaque Psoriasis. The trial will include 216 Moderate to Severe plaque psoriasis patients,and at the first stage they will be randomized divided into three group: full-dose of Qiangke® group, half-dose of Qiangke® group and placebo group.And the blind stage will last for 12 weeks. Then at the second stage, all patients will receive 50mg qw of Qiangke® for additional 12 weeks.

Condition or disease Intervention/treatment Phase
Plaque Psoriasis Psoriasis Biological: etanercept Biological: etanercept (half dose) Drug: placebo Phase 3

Detailed Description:

Psoriasis is a chronic inflammatory skin disease that can lead to significant physical and psychologic distress for patients.Recombinant Human TNF Receptor-Ig Fusion Protein for Injection (Qiangke®) can block the role of the cytokine tumor necrosis factor (TNF)-alpha.

TNF-α plays a major role in the pathophysiology of both Psoriasis(PsO)and Psoriatic Arthritis (PsA). TNF-α levels are elevated in psoriatic skin lesions, serum samples, and synovial fluid. Anti-TNF-α therapy has shown efficacy in treating psoriatic skin lesions, joint pain and swelling, enthesitis, and dactylitis plus the ability to improve mobility, reduce radiographic progression of disease, and influence quality of life parameters.

Qiangke® is a dimeric, soluble fusion protein consisting of the extracellular ligand binding portion of the TNF receptor linked to the Fc portion of human Immunoglobulin gamma-1(IgG1). It is capable of binding and neutralizing soluble TNF and transmembrane TNF. It alters neutrophil migration and dendritic cell and T-cell maturation and migration, thus decreasing the local and systemic production of pro-inflammatory cytokines and their subsequent effects.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 216 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Safety and Efficacy Study of Recombinant Human TNF Receptor-IgG Fusion Protein for Injection (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis
Study Start Date : January 2015
Estimated Primary Completion Date : January 2017
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis
Drug Information available for: Etanercept

Arm Intervention/treatment
Experimental: etanercept
Recombinant Human TNF Receptor-Ig Fusion Protein for Injection(Qiangke®) 50mg twice a week for 12 weeks, then Two vials of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week from Week 12 to Week 24
Biological: etanercept
Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50mg twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
Other Name: Qiangke®

Experimental: etanercept (half dose)
One vial of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection(Qiangke®) 25mg and one vial of placebo twice a week for 12 weeks, then Two vials of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week from Week 12 to Week 24
Biological: etanercept (half dose)
Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
Other Name: Qiangke®

Placebo Comparator: Placebo
Two vials of Placebo twice a week for 12 weeks, then Two vials of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection(Qiangke®) 25mg twice a week from Week 12 to Week 24
Drug: placebo
two vials of placebo twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.




Primary Outcome Measures :
  1. Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response at Week 12 [ Time Frame: Week 12 ]

Secondary Outcome Measures :
  1. Proportion of subjects achieving PASI 90 & 50 [ Time Frame: Week 12 ]
  2. Proportion of subjects achieving PASI 90 & 50 & 75 [ Time Frame: Week 24 ]
  3. Physician's Global Assessment (PGA) [ Time Frame: Week 12 & 24 ]
  4. Nail Psoriasis Severity Index (NAPSI) [ Time Frame: Week 12 & 24 ]
  5. Dermatology Life Quality Index (DLQI) [ Time Frame: Week 12 & 24 ]
  6. Patient's Global Assessment (PGA) [ Time Frame: Week 12 & 24 ]

Other Outcome Measures:
  1. Safety parameters - Number of Participants With Abnormal Laboratory Values and/or Adverse Events [ Time Frame: Week 12 & 24 ]
    Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or Female, age 18-65,Asian.
  2. Freely provides both verbal and written informed consent.
  3. Consent to use effective contraception during the trial period.
  4. Participant had a clinical diagnosis of psoriasis for at least 6 months, and had moderate to severe plaque psoriasis
  5. Participant must have a Psoriasis Area Severity Index score greater than or equal to 12 at the baseline visit and Body Surface Area involvement greater than or equal to 10% at the baseline visit.
  6. Participant has previous exposure to systemic psoriasis therapy or phototherapy, but not ideal.
  7. Meet the following criteria for Tuberculosis screening: A. has no prior history of occult or active tuberculosis. B. No signs or symptoms of active tuberculosis in history and / or physical examination. C. in the first 6 weeks of the trial, tuberculosis screening test meet the requirements of the trial.
  8. Laboratory screening results:Hemoglobin≥110g/L.White blood cell≥4 * 109 /L. Neutrophil≥1.5 * 109/L.Platelet≥100 * 109/L.Serum alanine aminotransferase and / or aspartate aminotransferase not more than 1.5 times of the upper limit of normal.Serum creatinine does not exceed 1.5 mg/dL (International units: ≤133 mol/L).
  9. During the first 2 weeks of the study, Participant must stop adjuvant therapy including traditional Chinese medicine and acupuncture.
  10. Hepatitis B (HBV) screening in compliance with the requirements of this test.
  11. Weight≥60Kg.

Exclusion Criteria:

  1. Pustular, erythrodermic, and/or guttate forms of psoriasis.
  2. Participant had treated with TNF antagonists within 6 weeks prior to the Baseline visit.
  3. Participant had treated with Other biological agents within 6 weeks prior to the Baseline visit.
  4. Participant had treated with Phototherapy or systemic antipsoriatic treatment (such as:Methotrexate(MTX), acitretin, cyclosporine, Total Glucosides of Paeony(TGP), treatment of psoriasis related Chinese medicines, etc.) and systemic corticosteroid treatment within 4 weeks prior to the Baseline visit.
  5. Participant had treated with Topical corticosteroid therapy, vitamin A or D analogue or Anthralin within 2 weeks prior to the Baseline visit.
  6. Participant received any drug that the drug's metabolism was less than 7 half lives before the Baseline visit.
  7. Participant plans to pregnant or breast feeding or father during the study.
  8. The history of occult or active granuloma infections, including histoplasmosis, coccidioidomycosis.
  9. Participant has suffered from Non Mycobacterium tuberculosis infection or opportunistic infections (such as cytomegalovirus sense of dyeing, Pneumocystis carinii pneumonia, aspergillosis) within 6 weeks prior to the Baseline visit.
  10. The close contact history of active tuberculosis patients or Tuberculosis screening results do not meet the requirements.
  11. Participant has suffered from severe infection (for example hepatitis, pneumonia, acute pyelonephritis or sepsis), or participant use intravenous antibiotics now because of infection within 6 weeks prior to the Baseline visit.
  12. Participant has suffered from chronic or recurrent infections before or at present, including (but not limited to) chronic kidney infection disease and chronic chest infectious diseases (such as bronchial dilation), sinusitis, recurrent urinary tract infections (such as recurrent pyelonephritis and chronic non remission cystitis), open, overflow liquid or infection of skin wound or ulcer.
  13. Human immunodeficiency virus (HIV) antibody positive.
  14. Hepatitis B virus (HBV) screening results do not meet the requirements.
  15. Hepatitis C virus (HCV) antibody positive.
  16. Participant has demyelinating diseases such as multiple sclerosis or optic neuritis.
  17. A history of congestive heart failure, including asymptomatic congestive heart failure.
  18. A history or sign of a lymph node hyperplasia, including lymphoma or suggestive of a possible sign such as the size and location of an enlarged lymph node or a history of clinically significant enlargement of the spleen.
  19. Participant has symptoms or signs of severe, progressive or uncontrolled kidney, liver, blood, gastrointestinal, endocrine, lung, heart, nerve, mental or brain diseases.
  20. There is a history of malignancy or previous history.
  21. Joint prosthesis has not yet been removed or replaced.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02701205


Contacts
Layout table for location contacts
Contact: Hongzhong Jin, M.D. 8613693583080 jinhongzhong@263.net

Locations
Layout table for location information
China, Beijing
Chinese Academy of Medical Sciences & Peking Union Medical College Recruiting
Beijing, Beijing, China, 100730
Contact: Hongzhong Jin, M.D.         
China, Jiangsu
Institute of Dermatology and Skin Disease Hospital Chinese Academy of Medical Sciences Recruiting
Nanjing, Jiangsu, China, 210042
Contact: Heng Gu, M.D.         
China, Shandong
Qilu Hospital of Shandong University Recruiting
Jinan, Shandong, China, 250012
Contact: Qing Sun, M.D.         
China, Shanghai
Changhai Hospital of The Second Military Medical University Recruiting
Shanghai, Shanghai, China, 200433
Contact: Jun Gu, M.D.         
Sponsors and Collaborators
Shanghai Celgen Bio-Pharmaceutical Co.,Ltd
Investigators
Layout table for investigator information
Principal Investigator: Hongzhong Jin, M.D. Chinese Academy of Medical Sciences Peking Union Medical College
Publications of Results:
Other Publications:
Layout table for additonal information
Responsible Party: Shanghai Celgen Bio-Pharmaceutical Co.,Ltd
ClinicalTrials.gov Identifier: NCT02701205    
Other Study ID Numbers: QRSTPP
First Posted: March 8, 2016    Key Record Dates
Last Update Posted: March 8, 2016
Last Verified: March 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Shanghai Celgen Bio-Pharmaceutical Co.,Ltd:
Plaque Psoriasis
Skin Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Etanercept
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Gastrointestinal Agents
Immunosuppressive Agents
Immunologic Factors